Skip to main content
SpringerLink
Log in

Should All Patients with Inflammatory Breast Cancer Undergo Autologous Stem Cell Transplant?

  • Chapter
Current Controversies in Bone Marrow Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

  • 104 Accesses

Abstract

Modern medicine has made great strides in the advancement of treatment strategies for diseases that were once considered incurable. The treatment of the most aggressive forms of breast cancer (BC), inflammatory breast cancer (IBC), has been included in medicine’s quest for cure. Unfortunately, determining the optimal treatment program for IBC is hampered by several characteristics of the disease, e.g., the rareness of the disease, the lack of consistency in diagnostic criteria, and the inclusion of other stages of BC in clinical trials involving IBC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Karlsson YA, et al. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide. Prognostic and therapeutic implications, Cancer, 83 (1998) 936–47.

    Article  PubMed  CAS  Google Scholar 

  2. Beahrs O, et al. Manual for Staging of Cancers, 3rd ed., Lippincott, Philadelphia, 1988, pp. 145–150.

    Google Scholar 

  3. Haagensen C. Diseases of the Breast, 2nd ed., Saunders, Philadelphia, 1971, pp. 576–584.

    Google Scholar 

  4. Levine SH, et al. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program, J. Natl. Cancer Inst., 74 (1985) 291–297.

    PubMed  CAS  Google Scholar 

  5. Lucas F and Perez-Mesa C. Inflammatory carcinoma of the breast, Cancer, 41 (1978) 1595–1605.

    Article  PubMed  CAS  Google Scholar 

  6. Brooks HL, et al. Inflammatory breast carcinoma: a community hospital experience, J. Am. Coll. Surg., 186 (1998) 622–629.

    Article  PubMed  CAS  Google Scholar 

  7. Schafer P, et al. Surgery as part of a combined modality approach for inflammatory breast carcinoma, Cancer, 59 (1987) 1063–1067.

    Article  PubMed  CAS  Google Scholar 

  8. Sener SF et al. Achieving local control for inflammatory carcinoma of the breast, Surg. Gynecol. Obstet., 175 (1992) 141–144.

    PubMed  CAS  Google Scholar 

  9. Fields JN, et al. Inflammatory carcinoma of the breast: treatment results on 107 patients, Int. J. Radiat. Oncol. Biol. Phys., 17 (1989) 249–255.

    Article  PubMed  CAS  Google Scholar 

  10. Fields JN, et al. Prognostic factors in inflammatory breast cancer, Cancer, 63 (1989) 1225–1232.

    Article  PubMed  CAS  Google Scholar 

  11. Chang S, et al. Inflammatory breast carcinoma incidence and survival. The Surveillance Epidemiology, and End Results Program of the National Cancer Institute, 1975–1992, Cancer, 82 (1998) 2366–2372.

    Article  PubMed  CAS  Google Scholar 

  12. Jaiyesimi IA, Buzdar AU, and Hortobagyi G. Inflammatory breast cancer: a review, J. Clin. Oncol., 10 (1992) 1014–1024.

    PubMed  CAS  Google Scholar 

  13. Lopez MJ and Porter KA. Inflammatory breast cancer, Surg. Clin. North Am., 76 (1996) 411–429.

    Article  CAS  Google Scholar 

  14. Ackland SP, Bitran JD, and Dowlatshahi K. Management of locally advanced and inflammatory carcinoma of the breast, Surg. Gynecol. Obstet., 161 (1985) 399–408.

    PubMed  CAS  Google Scholar 

  15. Honkoop AH, Wagstaff J, and Pinwso HM. Management of stage HI breast cancer, Oncology, 55 (1998) 218–227.

    Article  PubMed  CAS  Google Scholar 

  16. Grace WR and Cooperman AM. Inflammatory breast cancer, Surg. Clin. North Am., 65 (1985) 151–160.

    PubMed  CAS  Google Scholar 

  17. Mourali N. Ten-year results utilizing chemotherapy as primary treatment in nonmetastic, rapidly progressing breast cancer Cancer Invest. 11 (1993) 363–370

    Google Scholar 

  18. Thomas J, William W. Multimodal treatment for inflammatory breast cancer Int. J. Radiat. Oncol. Biol. Phys. 17 (1989) 739–745.

    Google Scholar 

  19. Chu A, Wood WC, and Doucette JA. Inflammatory carcinoma of the breasts treated by radical radiotherapy, Cancer, 45 (1980) 2730–2737.

    Article  PubMed  CAS  Google Scholar 

  20. Duggan D. Local therapy of locally advanced breast cancer, Oncology,5 (1991) 67–74,79–80,82.

    Google Scholar 

  21. Sherry MM. Inflammatory carcinoma of the breast, Am. J. Med., 79 (1985) 355–364.

    Article  PubMed  CAS  Google Scholar 

  22. Hobar PC. Multimodality treatment of locally advanced breast carcinoma Arch. Surg.123 (1988) 951–955.

    Google Scholar 

  23. Hortobagyi GN. Primary chemotherapy for early and advanced breast cancer Cancer Lett.90 (1995) 103–109.

    Google Scholar 

  24. Ragaz J. Chemotherapy and hormonal therapy in stage III disease; inflammatory breast cancer Curr. Opin. Oncol.2 (1990) 1068–1087.

    Google Scholar 

  25. Thomas F. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy, Cancer, 76 (1995) 2286–2290.

    Article  PubMed  CAS  Google Scholar 

  26. Jacquillat C. Neoadjuvant chemotherapy of breast cancer, Drugs Under Exp. Clin Res., XII (1986) 147–152.

    Google Scholar 

  27. Frank JL. Stage III breast cancer: is neoadjuvant chemotherapy always necessary J. Surg. Oncol.49 (1992) 220–225.

    Google Scholar 

  28. Pisansky TM. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy, Am. J. Clin. Oncol., 15 (1992) 376–387.

    Article  PubMed  CAS  Google Scholar 

  29. Rubens RD. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC breast cancer co-operative group trial (10792)*, Eur. J. Cancer Clin. Oncol.,25 (1989) 667–678.

    Google Scholar 

  30. Rouesse J. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy J. Clin. Oncol.4 (1986) 1765–1771.

    Google Scholar 

  31. Arriagada R. Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer, Int. J. Radiat. Oncol. Biol. Phys., 19 (1990) 1207–1210.

    Article  PubMed  CAS  Google Scholar 

  32. Jones AL, et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen, J. Clin. Oncol., 12 (1994) 1259–1265.

    PubMed  CAS  Google Scholar 

  33. Bonnefoi H, et al. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen, Br. J. Cancer, 73 (1996) 391–396.

    Article  PubMed  CAS  Google Scholar 

  34. Gurney H, et al. Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin, Aust. NZ J. Med., 28 (1998) 400–402.

    Article  CAS  Google Scholar 

  35. Danforth J, David N. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer, Am. Surg.56 (1990) 6–11.

    Google Scholar 

  36. Calderoli H de Manzini N, and Keiling R. Role of chemotherapy in acute breast cancer. Analysis of 41 cases, Int. Surg.,73 (1988) 112–115.

    Google Scholar 

  37. Israel L, Breau J-L, and Morere J-F. Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas, Cancer, 57 (1986) 24–28.

    Article  PubMed  CAS  Google Scholar 

  38. Morrell LE, et al. A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma, Cancer, 82 (1998) 503–511.

    Article  PubMed  CAS  Google Scholar 

  39. Mourali N, et al. Preliminary results of primary systemic chemotherapy in association with surgery or radiotherapy in rapidly progressing breast cancer, Cancer, 45 (1982) 367–374.

    Article  CAS  Google Scholar 

  40. Perloff M, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a cancer and leukemia group B study, J. Clin. Oncol., 6 (1988) 261–269.

    PubMed  CAS  Google Scholar 

  41. Koh EH, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach: M.D. Anderson Cancer Center experience, Cancer Chemother. Pharmacol., 27 (1990) 94–100.

    Article  PubMed  CAS  Google Scholar 

  42. Pierce LJ, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer, Int. J. Radiat. Oncol. Biol. Phys., 23 (1992) 949–960.

    Article  PubMed  CAS  Google Scholar 

  43. Brun B, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation, Cancer, 61 (1988) 1096–1103.

    Article  PubMed  CAS  Google Scholar 

  44. Knight J, Charles D, et al. Surgical considerations after chemotherapy and radiation therapy for inflammatory breast cancer, Surgery, 99 (1986) 385–391.

    PubMed  Google Scholar 

  45. Pawlicki M, Skolyszewski J, and Brandys A. Results of combined treatment of patients with locally advanced breast cancer, Tumori, 69 (1983) 249–253.

    PubMed  CAS  Google Scholar 

  46. Buzdar AU, et al. Combined modality treatment of stage III and inflammatory breast cancer, Surg. Oncol. Clin. North Am., 4 (1995) 715–734.

    CAS  Google Scholar 

  47. Ueno NT, et al. Combined-mobility treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center, Cancer Chemother. Pharmacol., 40 (1997) 321–329.

    Article  PubMed  CAS  Google Scholar 

  48. Colozza M, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclosphosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results, Am. J. Clin. Oncol., 19 (1) (1996) 10–17.

    Article  PubMed  CAS  Google Scholar 

  49. Maloisel F, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast, Cancer, 65 (1990) 851–855.

    Article  PubMed  CAS  Google Scholar 

  50. Pisansky TM, et al. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma, Cancer, 77 (1996) 2520–2528.

    Article  PubMed  CAS  Google Scholar 

  51. Fleming RYD, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma, Ann. Surg. Oncol., 4 (1997) 452–461.

    Article  PubMed  CAS  Google Scholar 

  52. lino Y. Multidisciplinary treatment with anthracyclines in inflammatory breast cancer, Anticancer Res, 16 (1996) 3111–3116.

    Google Scholar 

  53. Bauer RL,. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy, Ann. Surg. Oncol., 2 (1995) 288–294.

    Article  PubMed  CAS  Google Scholar 

  54. Attia-Sobol JF, Jean-Pierr. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis, Eur. J. Cancer., 29A (1993) 1081–1088.

    Article  Google Scholar 

  55. Rouesse J. Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors, Breast Cancer Res. Treatment, 16 (1990) 15–22.

    Article  CAS  Google Scholar 

  56. Teicher BA. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination, Semin. Oncol., 17 (Supp13) (1990) 18–32.

    Google Scholar 

  57. Henderson IC, Hayes DF, and Gelman R. Dose-response in the treatment of breast cancer: a critical review, J. Clin. Oncol., 6 (1988) 1501–1515.

    PubMed  CAS  Google Scholar 

  58. Zujewski J, Nelson A, and Abrams J. Much ado about not… enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer, J. Natl. Cancer Inst., 90 (1998) 200–209.

    Article  PubMed  CAS  Google Scholar 

  59. Hryniuk W and Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer, J. Clin. Oncol., 2 (1984) 1281–1288.

    PubMed  CAS  Google Scholar 

  60. Tannock IF. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer, J. Clin. Oncol.,6 (1988) 13771387.

    Google Scholar 

  61. Hryniuk W and Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer, J. Clin. Oncol., 4 (1986) 1162–1170.

    PubMed  CAS  Google Scholar 

  62. Geller NL, et al. Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy, Cancer, 66 (1990) 1678–1684.

    Article  PubMed  CAS  Google Scholar 

  63. Bonadonna G and Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer, N. Engl. J. Med., 304 (1981) 10–15.

    Article  PubMed  CAS  Google Scholar 

  64. Buzdar AU. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte a-interferon for stage II or III breast cancer, J. Clin. Oncol.,10 (1992)15401546.

    Google Scholar 

  65. Hortobagyi GN, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study, J. Clin. Oncol., 5 (1987) 354–364.

    PubMed  CAS  Google Scholar 

  66. Ang P.-T. et al. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma, J. Clin. Oncol., 7 (1989) 1677–1684.

    PubMed  CAS  Google Scholar 

  67. Fetting JH, et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an intergroup study, J. Clin. Oncol., 16 (1998) 2382–2391.

    PubMed  CAS  Google Scholar 

  68. Abeloff MD, et al. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer, J. Natl Cancer Inst., 82 (1990) 570–574.

    Article  PubMed  CAS  Google Scholar 

  69. Budman DR, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer, J. Natl. Cancer Inst., 90 (1998) 1205–1211.

    Article  PubMed  CAS  Google Scholar 

  70. Wood WC, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma, N. Engl. J. Med., 330 (1994) 1253–1259.

    Article  PubMed  CAS  Google Scholar 

  71. Budman DR. A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443, Cancer Invest, 8 (1990) 571–575.

    Article  PubMed  CAS  Google Scholar 

  72. Thor AD. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer, J. Natl. Cancer Inst.,90 (1998) 1346–1360.

    Google Scholar 

  73. Prost S, et al. Association of c-erb B2-gene amplification with poor prognosis in noninflammatory breast carcinomas but not in carcinomas of the inflammatory type, Int. J. Cancer, 58 (1994) 763–768.

    Article  PubMed  CAS  Google Scholar 

  74. Viens P, et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome, Bone Marrow Transplant, 21 (1998) 249–254.

    Article  PubMed  CAS  Google Scholar 

  75. Wolmark N, Fisher B, and Anderson S. The effect of increasing dose intensity and cumulative dose of adjuvant cyclophosphamide in node positive breast cancer: results of NSABP B-25, Breast Cancer Res. Treatment, 46 (1997) 26.

    Google Scholar 

  76. Fisher B, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicincyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22, J. Clin. Oncol., 15 (1997) 1858–1869.

    PubMed  CAS  Google Scholar 

  77. Bonadonna G, Zambetti M, and Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes, DAMA, 273 (1995) 542–547.

    Google Scholar 

  78. Hudis C. Is there an alternative to alternating adjuvant therapy for breast cancerCancer Invest, 12 (1994) 329–335.

    Article  PubMed  CAS  Google Scholar 

  79. Hudis C. Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide, Oncology, II (Suppl. 3 ) (1997) 15–18.

    Google Scholar 

  80. Armstrong DK, et al. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer, Breast Cancer Res. Treatment, 28 (1993) 277–284.

    Article  CAS  Google Scholar 

  81. Feldman LD. Pathological assessment of response to induction chemotherapy in breast cancer, Cancer Res, 46 (1986) 2578–2581.

    Google Scholar 

  82. Palangie T, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications, Eur. J. Cancer, 30A (1994) 921–927.

    Article  Google Scholar 

  83. Ferriere JP, et al. Primary chemotherapy in breast cancer, Am. J. Clin. Oncol., 21 (1998) 117–120.

    Article  PubMed  CAS  Google Scholar 

  84. Chevallier B, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate, Am. J. Clin. Oncol., 16 (1993) 223–228.

    Article  PubMed  CAS  Google Scholar 

  85. Brockstein BE and Williams SF. High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow, Stem Cells, 14 (1996) 79–89.

    Article  PubMed  CAS  Google Scholar 

  86. Meropol NJ, Overmoyer BA, and Stadtmauer EA. High-dose chemotherapy with autologous stem cell support for breast cancer, Oncology, 6 (1992) 53–69.

    PubMed  CAS  Google Scholar 

  87. Fields KK. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer, Semin. Oncol., 25 (Suppl 4) (1998) 1–6.

    Google Scholar 

  88. Myers SE and Williams SF. Role of high-dose chemotherapy and autologous stem cell support in treatment of breast cancer, Hematol. Oncol. Clin. North Am., 7 (1993) 631–645.

    PubMed  CAS  Google Scholar 

  89. von Schilling C and Herrmann F. Dose-intensified treatment of breast cancer: current results, J. Mol. Med., 73 (1995) 611–627.

    Article  Google Scholar 

  90. Safah H and Weiner RS. The role of bone marrow transplantation in the management of advanced local disease, Surg. Oncol. Clin. North Am., 4 (1995) 735–749.

    CAS  Google Scholar 

  91. Cooper BW, et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer, J. Clin. Oncol., 16 (1998) 3509–3517.

    PubMed  CAS  Google Scholar 

  92. Bergh J High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer, Acta Oncol,34 (1995) 669–674.

    Google Scholar 

  93. Vandat L and Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer, Curr. Opin. Hematol., 4 (1997) 381–389.

    Article  Google Scholar 

  94. Joensuu H. Autologous stem cell transplantation in breast cancer, Ann. Med., 28 (1996) 145–149.

    Article  PubMed  CAS  Google Scholar 

  95. de Graaf H, et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes, Eur. J. Cancer, 30A (1994) 150–153.

    Article  Google Scholar 

  96. Bearman SI, et al. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodes, Bone Marrow Transplant, 20 (1997) 931–937.

    Article  PubMed  CAS  Google Scholar 

  97. Gianni AM, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results, J. Clin. Oncol., 15 (1997) 2312–2321.

    PubMed  CAS  Google Scholar 

  98. Cagnoni PJ, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer, J. Clin. Oncol., 16 (1998) 1661–1668.

    PubMed  CAS  Google Scholar 

  99. Peters WP, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer, J. Clin. Oncol., 11 (1993) 1132–1143.

    PubMed  CAS  Google Scholar 

  100. Holland HK, Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplating plus autologous marrow/stem-cell transplantation and comprehensive supportive care, J. Clin. Oncol.,14 (1996) 1156–1164.

    Google Scholar 

  101. Vaughan WP. Autologous bone marrow transplantation in the treatment of breast cancer: clinical and technologic strategies, Semin. Oncol., 20 (Suppl 6) (1993) 55–58.

    Google Scholar 

  102. Marks LB, et al. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with >_10 positive axillary lymph nodes, Int. J. Radiat. Oncol. Biol. Phys., 23 (1992) 1021–1026.

    Article  PubMed  CAS  Google Scholar 

  103. Marks LB, et al. Impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer, Cancer, 74 (1994) 2964–71.

    Article  PubMed  CAS  Google Scholar 

  104. Lalisang RI, et al. High-dose chemotherapy with autologous bone marrow support as consolidation after standard adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes, Bone Marrow Transplant, 21 (1998) 243–247.

    Article  PubMed  CAS  Google Scholar 

  105. Dillman RO, et al. High-dose chemotherapy with autologous stem cell rescue in breast cancer, Breast Cancer Res. Treatment, 37 (1996) 277–289.

    Article  CAS  Google Scholar 

  106. Antman K, et al. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age, Monogr. Natl. Cancer Inst., 16 (1994) 91–94.

    PubMed  Google Scholar 

  107. Peters WP, et al. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving >_10 axillary lymph nodes (DUKE/CALGB 8782), Proc. ASCO, 14 (1995) 317.

    Google Scholar 

  108. Somlo G, et al. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer, Cancer, 73 (1994) 1678–1685.

    Article  PubMed  CAS  Google Scholar 

  109. Fields KK, et al. Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase VII study in breast cancer patients, Surg. Oncol., 2 (1993) 87–95.

    Article  PubMed  CAS  Google Scholar 

  110. Mulder NH, et al. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer, Eur. J. Cancer, 29A (1993) 668–671.

    Article  Google Scholar 

  111. Ravagnani F, et al. Clinical application of growth factors for collection of circulating hematopoietic progenitors in breast cancer patients treated with high-dose cyclophosphamide, Int. J. Artif. Organs., 16 (1993) 35–38.

    PubMed  Google Scholar 

  112. Bregni M. High-dose cyclophosphamide in patients with operable breast cancer: recombinant human GM-CSF ameliorates drug-induced leukopenia and thrombocytopenia, Haematologica,75 (Suppl 1) (1990) 95–98.

    Google Scholar 

  113. Raxis ED, et al. TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer, J. Med., 25 (1994) 241–250.

    Google Scholar 

  114. Ayash LJ. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma, J. Clin. Oncol., 16 (1998) 1000–1007.

    PubMed  CAS  Google Scholar 

  115. Ayash LJ. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience, J. Hematother., 2 (1993) 507–511.

    Google Scholar 

  116. Rosti G. Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients, Ann. Oncol., 6 (1995) 1045–1047.

    PubMed  CAS  Google Scholar 

  117. Somolo G. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival, J. Clin. Oncol.,15 (1997) 28822893.

    Google Scholar 

Download references

Authors
  1. Beth A. Overmoyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Brian J. Bolwell MD (Director, Staff Physician) (Director, Staff Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Overmoyer, B.A. (2000). Should All Patients with Inflammatory Breast Cancer Undergo Autologous Stem Cell Transplant?. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-657-7_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9812-7

  • Online ISBN: 978-1-59259-657-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation